BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 31978562)

  • 1. Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of Breast Cancer Patients.
    Shishido SN; Welter L; Rodriguez-Lee M; Kolatkar A; Xu L; Ruiz C; Gerdtsson AS; Restrepo-Vassalli S; Carlsson A; Larsen J; Greenspan EJ; Hwang ES; Waitman KR; Nieva J; Bethel K; Hicks J; Kuhn P
    J Mol Diagn; 2020 Mar; 22(3):319-337. PubMed ID: 31978562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment response and tumor evolution: lessons from an extended series of multianalyte liquid biopsies in a metastatic breast cancer patient.
    Welter L; Xu L; McKinley D; Dago AE; Prabakar RK; Restrepo-Vassalli S; Xu K; Rodriguez-Lee M; Kolatkar A; Nevarez R; Ruiz C; Nieva J; Kuhn P; Hicks J
    Cold Spring Harb Mol Case Stud; 2020 Dec; 6(6):. PubMed ID: 33203646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer.
    Keup C; Suryaprakash V; Hauch S; Storbeck M; Hahn P; Sprenger-Haussels M; Kolberg HC; Tewes M; Hoffmann O; Kimmig R; Kasimir-Bauer S
    Genome Med; 2021 May; 13(1):85. PubMed ID: 34001236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy in breast cancer: A comprehensive review.
    Alimirzaie S; Bagherzadeh M; Akbari MR
    Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
    Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
    Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision oncology using a limited number of cells: optimization of whole genome amplification products for sequencing applications.
    Sho S; Court CM; Winograd P; Lee S; Hou S; Graeber TG; Tseng HR; Tomlinson JS
    BMC Cancer; 2017 Jul; 17(1):457. PubMed ID: 28666423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients.
    Martignano F; Munagala U; Crucitta S; Mingrino A; Semeraro R; Del Re M; Petrini I; Magi A; Conticello SG
    Mol Cancer; 2021 Feb; 20(1):32. PubMed ID: 33579306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
    Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
    Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers.
    Miller BF; Pisanic Ii TR; Margolin G; Petrykowska HM; Athamanolap P; Goncearenco A; Osei-Tutu A; Annunziata CM; Wang TH; Elnitski L
    Clin Epigenetics; 2020 Oct; 12(1):154. PubMed ID: 33081832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers.
    Venesio T; Siravegna G; Bardelli A; Sapino A
    Pathobiology; 2018; 85(1-2):146-154. PubMed ID: 28614831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosomal Instability Estimation Based on Next Generation Sequencing and Single Cell Genome Wide Copy Number Variation Analysis.
    Greene SB; Dago AE; Leitz LJ; Wang Y; Lee J; Werner SL; Gendreau S; Patel P; Jia S; Zhang L; Tucker EK; Malchiodi M; Graf RP; Dittamore R; Marrinucci D; Landers M
    PLoS One; 2016; 11(11):e0165089. PubMed ID: 27851748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications.
    Earl J; Calabuig-Fariñas S; Sarasquete ME; Muinelo Romay L; Lopez-Tarruella S; Bellosillo Paricio B; Rodríguez M; Valencia Leoz K; Dueñas Porto M; Tarazona N; Hernandez Losa J; Toledo RA
    J Vis Exp; 2022 Sep; (187):. PubMed ID: 36190291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Preanalytical Conditions and Implementation of Quality Control Steps for Reliable Gene Expression and DNA Methylation Analyses in Liquid Biopsies.
    Zavridou M; Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Lianidou E
    Clin Chem; 2018 Oct; 64(10):1522-1533. PubMed ID: 30018056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.
    Gale D; Lawson ARJ; Howarth K; Madi M; Durham B; Smalley S; Calaway J; Blais S; Jones G; Clark J; Dimitrov P; Pugh M; Woodhouse S; Epstein M; Fernandez-Gonzalez A; Whale AS; Huggett JF; Foy CA; Jones GM; Raveh-Amit H; Schmitt K; Devonshire A; Green E; Forshew T; Plagnol V; Rosenfeld N
    PLoS One; 2018; 13(3):e0194630. PubMed ID: 29547634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and treatment monitoring in breast cancer: how liquid biopsy can support patient management.
    Cucchiara F; Scarpitta R; Crucitta S; Scatena C; Arici R; Naccarato AG; Fogli S; Danesi R; Del Re M
    Pharmacogenomics; 2022 Jan; 23(2):119-134. PubMed ID: 35006002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preanalytical variables that affect the outcome of cell-free DNA measurements.
    Ungerer V; Bronkhorst AJ; Holdenrieder S
    Crit Rev Clin Lab Sci; 2020 Nov; 57(7):484-507. PubMed ID: 32393081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
    Pagès M; Rotem D; Gydush G; Reed S; Rhoades J; Ha G; Lo C; Fleharty M; Duran M; Jones R; Becker S; Haller M; Sinai CE; Goumnerova L; Golub TR; Love JC; Ligon KL; Wright KD; Adalsteinsson VA; Beroukhim R; Bandopadhayay P
    Neuro Oncol; 2022 Aug; 24(8):1352-1363. PubMed ID: 34984433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric liquid biopsy analysis in metastatic prostate cancer.
    Hodara E; Morrison G; Cunha A; Zainfeld D; Xu T; Xu Y; Dempsey PW; Pagano PC; Bischoff F; Khurana A; Koo S; Ting M; Cotter PD; Moore MW; Gunn S; Usher J; Rabizadeh S; Danenberg P; Danenberg K; Carpten J; Dorff T; Quinn D; Goldkorn A
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30702443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and achievements of liquid biopsy technologies employed in early breast cancer.
    Alba-Bernal A; Lavado-Valenzuela R; Domínguez-Recio ME; Jiménez-Rodriguez B; Queipo-Ortuño MI; Alba E; Comino-Méndez I
    EBioMedicine; 2020 Dec; 62():103100. PubMed ID: 33161226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of
    Cayrefourcq L; Alix-Panabières C
    Expert Rev Mol Diagn; 2020 Sep; 20(9):913-919. PubMed ID: 32856493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.